Scholarlink

Purpose of the Review <p>Review the efficacy and safety of IL2319 inhibitors in the management of IBD.</p> Recent Findings <p>Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD.</p> Summary <p>IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

New Kids on the Block: IL-23 Inhibitors in IBD Management

  • 期刊论文

  • 发表日期：

    2025年10月22日

查看全文
  • Jacob Jones,
  • Jeevin Sandhu,
  • Kara Jones,
  • David Dulaney,
  • Anish Patel

摘要

Purpose of the Review

Review the efficacy and safety of IL2319 inhibitors in the management of IBD.

Recent Findings

Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD.

Summary

IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.